



FOR IMMEDIATE RELEASE

## **New World Angels Invests \$1.2MM into Swift Sync NWA Leads Funding for Clinical Trials**

BOCA RATON, FL (May 14, 2021) – New World Angels (“NWA”) ([www.newworldangels.com](http://www.newworldangels.com)), Florida’s premier structured angel investment group, announced today that it has completed a \$1.2 million investment into Swift Sync Inc. (“Swift Sync”), leading a \$3.5MM round to fund Swift Sync’s advancement in product development and clinical trials for its revolutionary medical device technology. NWA is joined by OceanAzul, Swift Sync management, and other investors in the Series A funding round.

Miami-based Swift Sync has developed a temporary, disposable, dual-chamber pacing catheter. Temporary cardiac pacing involves electrical cardiac stimulation to treat arrhythmia during surgery and emergency procedures. Unlike currently available catheters which pace only the right ventricle, Swift Sync’s synchronous dual chamber pacing technology can increase cardiac blood-flow by up to 50% relative to conventional single chamber ventricular pacing. The catheter is easier to deploy and more stable around the heart due to patented features, including nitinol insulated leads and platinum-iridium tips. The device can be used up to seven days and provides synchronous dual chamber pacing previously only available via more intrusive open-heart surgery and suturing.

Swift Sync was co-founded by Dr. Eduardo de Marchena and Dr. Christian Marin y Kall based on their early work at University of Miami, and the technology has been exclusively licensed to the company. Further work by the co-founders has led to more recent patent filings perfecting the device. Joining the co-founders is veteran medical business leader Rick Toren who has become CEO. Human trials in the LATAM region are planned for late 2021.

Dr. David Schimel co-led NWA’s due diligence efforts along with NWA president Steve O’Hara. Team members included Dr. Andrew Yin, Jay DeGeare, Ron Grau, Rhys Williams and Ken Rubenstein. Dr. Yin, who is a practicing cardiac electrophysiologist in Naples, FL, commented, “If successful in clinical trials, this could be a game changer not only for its improved cardiac output during very sensitive procedures, but also because of its greater stability around the heart.”

Palm Beach County-based retired patent attorney Ken Rubenstein will join the company’s board of directors, which will include Dr. de Marchena, CEO Toren, University of Miami entrepreneur-in-residence Bob Williamson, and OceanAzul director Bill Pruitt.

Swift Sync co-founder Dr. de Marchena commented, “We are excited to add experienced medical investors from New World Angels to our strong venture investor group to aid in Swift Sync’s final development and successful launch. The \$3.5 million raised from this Series A round will allow completion of product development and securing FDA approval”.

### **About New World Angels:**

New World Angels (NWA) ([www.newworldangels.com](http://www.newworldangels.com)) is a group of 78 accredited, private investors, operators and entrepreneurs dedicated to providing equity capital and guidance to early-stage entrepreneurial companies with a strong presence in Florida. Members of NWA have extensive experience in founding, building, and managing companies in a wide variety of industries. NWA members are involved in the entrepreneurial communities from Miami to Jupiter on Florida’s east coast and from Naples to Tampa on Florida’s west coast, as well as a growing presence in Orlando. NWA has invested over \$27MM in growing US and international companies that either are based in Florida or have a strong presence in the state. In addition to providing funding, NWA members make their expertise and resource networks available to portfolio companies to facilitate a company’s growth.

### **About Swift Sync**

Founded by Dr. Eduardo de Marchena and Dr. Christian Marin y Kall, Swift Sync is developing its temporary synchronous dual chamber pacing catheter to improve certain heart rhythm emergencies, cardiac surgeries and interventional cardiology outcomes by re-establishing cardiac rhythm - improving heart output and reducing any complications from lead displacement. Its patented device has completed EVT pilot tests in 10 humans and is now moving towards clinical trials to gain FDA approval to go to market.

### **MEDIA CONTACTS:**

New World Angels

Sarah Lucas

COO

(617) 894-5156

[sarah@NewWorldAngels.com](mailto:sarah@NewWorldAngels.com)

Swift Sync

Rick Toren

CEO

(305) 903-6803

[rtoren@swiftsync.net](mailto:rtoren@swiftsync.net)